Researchers are increasingly linking the body’s circadian clock to cancer biology and treatment response, and they say timing medicines to a patient’s internal rhythm-chronotherapy-could lower toxicity and, in some cases, improve outcomes. The circadian system, driven by a central clock in the brain and peripheral clocks in tissues, controls DNA repair, cell division, hormone release, metabolism and immune function. Disrupting these rhythms-through shift work, nighttime light exposure, or sleep disturbance-has been epidemiologically associated with higher rates of some cancers and with worse symptoms, fatigue and quality of life in people with cancer.
At the molecular level, clock genes such as CLOCK and BMAL1 regulate PERIOD and CRYPTOCHROME proteins and interact with cancer pathways including c-Myc, Wnt/β‑catenin and Akt/mTOR. Depending on tumor type and context, clock proteins can either suppress or promote tumor growth; for example, BMAL1 influences p53 activity and the unfolded protein response, which affects cancer cell survival. In patients, altered rest-activity patterns and flattened diurnal cortisol have been studied as markers of circadian disruption and prognosis, though causation remains unproven.
Clinical studies of chronotherapy-timing chemotherapy, immunotherapy or radiotherapy to biological rhythms-have produced mixed but promising results. A systematic review of 18 randomized trials found that chronomodulated chemotherapy reduced toxicity in about 61% of studies but improved efficacy in only 17%. Specific timing patterns have been associated with fewer side effects: doxorubicin given in the morning (around 06:00) and cisplatin in the evening (roughly 16:00–20:00) showed lower complications in ovarian, recurrent endometrial and metastatic bladder cancer cohorts. Retrospective data in advanced melanoma suggest later-day immune‑checkpoint inhibitor infusions (for patients receiving ≥20% of doses after 4:30 pm) correlated with poorer survival, though this is observational and not proof of causation. As one review put it, “Anticancer therapy could take advantage of the mitotic rhythmicity of cells and apply the treatment depending on the time-of-day efficacy.”
Evidence for time-of-day effects in radiotherapy is inconsistent: some studies report differences in response or toxicity, while others-such as trials in high‑grade glioma-find no survival differences between morning and afternoon treatment. Overall, reducing treatment-related toxicity appears the more consistent benefit of chronoradiotherapy than clear gains in tumor control.
Implementing chronotherapy faces practical and biological hurdles. Hospital schedules, patient chronotypes, age, sex, comorbidities, drug regimens and tumor genetics all affect optimal timing. Tumors may maintain their own clocks and respond differently to systemic cues like glucocorticoids, feeding, and temperature.
New tools could help personalize timing. Wearables, smartwatches and research-grade actigraphy can track sleep and activity rhythms; biosensors and temperature or biochemical monitoring may estimate circadian phase. Computational models and programmable drug-delivery systems-possibly guided by AI-offer future promise but require prospective clinical validation. Meanwhile, circadian-supportive measures such as bright-light therapy, cognitive behavioral therapy for insomnia and exercise can improve sleep and fatigue, though evidence they extend survival is limited. Robust biomarkers and well-designed trials will be essential before chronotherapy becomes routine in cancer care.
Original Source: https://www.news-medical.net/health/Circadian-Oncology-Timing-Cancer-Treatment-and-Patient-Outcomes.aspx
Category:
Tags:
Publish Date: 2026-08-13 05:53:00
